HW
RIGL icon

Hancock Whitney’s Rigel Pharmaceuticals RIGL Stock Holding History

Hancock Whitney’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,044
Closed -$89K – 783
2021
Q2 		$89K Buy
2,044
+17
+0.8% +$642 ﹤0.01% 811
2021
Q1 		$69K Hold
2,027
– – ﹤0.01% 769
2020
Q4 		$71K Buy
+2,027
New +$58.7K ﹤0.01% 781

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Hancock Whitney's RIGL Position: Q3 2021 in Review

Hancock Whitney sold out of Rigel Pharmaceuticals (RIGL) in Q3 2021, closing a stake of 2,044 shares — an estimated $89K sold.

Hancock Whitney first reported a position in RIGL in Q4 2020 and held it in 3 quarters. The position peaked at $89K in Q2 2021. 163 funds tracked by Wall St. Rank hold RIGL as of Q3 2021.

  • Hancock Whitney reported no remaining Rigel Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Hancock Whitney sold 2,044 Rigel Pharmaceuticals shares in Q3 2021, an estimated $89K.
  • Hancock Whitney first reported a position in Rigel Pharmaceuticals in Q4 2020 and held it in 3 quarters.
  • Hancock Whitney's Rigel Pharmaceuticals position peaked at $89K in Q2 2021.
  • 163 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2021.

Based on Hancock Whitney's 13F filing for Q3 2021, filed 4 Nov 2021.